U.S. and Europe's selected anti-CD19 Car-T therapy sales forecast 2024
By 2024, Yescarta, a Car-T therapy from Gilead Sciences, is expected to have the largest revenue in both regions with 966 million U.S. dollars in the United States and 321 million U.S. dollars in Europe. This statistic shows the estimated 2024 revenues for selected anti-CD19 Car-T therapy in the U.S. and in Europe.